Logo

Ciphergen Receives Non-Compliance Notice from Nasdaq

Jul 03, 2006
NEW YORK (GenomeWeb News) - The Nasdaq exchange has notified Ciphergen Biosystems that it is subject to delisting because its market capitalization has fallen below $50 million for 10 consecutive business days.
 
Ciphergen said on Friday that it received the notice from Nasdaq's Listings Qualification Department on June 26.
 
Nasdaq had previously told the company that it had a period of 30 calendar days, or until June 23, to regain compliance.
 
Ciphergen said that it will request a hearing before a Nasdaq Listing Qualifications Panel to appeal the determination.

Filed under

Proteomics & Protein Research
proteomics
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.